<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405909</url>
  </required_header>
  <id_info>
    <org_study_id>DEGUM CEUS HCC</org_study_id>
    <nct_id>NCT03405909</nct_id>
  </id_info>
  <brief_title>Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study</brief_title>
  <acronym>ESCULAP</acronym>
  <official_title>Standardized Contrast-enhanced Ultrasound (CEUS) -Algorithms for the Non-invasive Diagnosis of Hepatocellular Carcinoma (HCC) in High-risk-patients - a Prospective German Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Erlangen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this prospective national multicenter study is to improve standardization of
      contrast-enhanced ultrasound (CEUS) in the non-invasive diagnosis of hepatocellular carcinoma
      (HCC) in high-risk patients.

      The study is funded by the German Society for Ultrasound in Medicine (DEGUM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, CEUS criteria for non-invasive diagnosis of HCC include arterial phase
      hyperenhancement, followed by contrast washout in the portal venous or late phase. We would
      like to investigate the following points:

        1. whether arterial hyperenhancement alone is sufficient for the definite diagnosis of HCC
           in cirrhosis with CEUS

        2. whether a further clearly-defined point of assessment in the late phase after 4-6
           minutes is of additional diagnostic value in focal liver lesions showing no contrast
           washout after 3 minutes

        3. diagnostic value of CEUS-based standardised diagnostic algorithms (ESCULAP = Erlanger
           Synopsis of Contrast Enhanced Ultrasound for Liver lesion Assessment in Patients at
           risk; CEUS LI-RADS = Contrast Enhanced Ultrasound Liver Imaging Reporting and Data
           System) for non-invasive diagnosis of HCC in high-risk patients (diagnostic accuracy,
           interobserver-variability, feasability in clinical Routine).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic value of standardised CEUS-based algorithms for the non-invasive diagnosis of HCC in high-risk patients</measure>
    <time_frame>2 years</time_frame>
    <description>Diagnostic accuracy, interobserver-variabilty and feasability in clinical routine for CEUS-based algorithms Reference Standard: histology / MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic value / dispensability of contrast washout for definite diagnosis of HCC with CEUS</measure>
    <time_frame>2 years</time_frame>
    <description>Sensitvity, specificity, positive and negative predictive value of arterial hyperenhancement only compared with arterial hyperenhancement followed by contrast washout for non-invasive diagnosis of HCC in high-risk patients Reference Standard: histology / MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardisation of CEUS examinations</measure>
    <time_frame>2 years</time_frame>
    <description>Diagnostic value of an additional standardised examination point in the late phase after 4-6 minutes in lesions without contrast washout after 3 minutes Reference Standard: histology / MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of CEUS in intrahepatic cholangiocellular carcinoma (ICC)</measure>
    <time_frame>2 years</time_frame>
    <description>Sensitvity, specificity, positive and negative predictive value of contrast-enhanced ultrasound for non-invasive diagnosis of ICC in high-risk patients / differential diagnosis of HCC versus ICC Reference Standard: histology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of two CEUS-based algorithms</measure>
    <time_frame>2 years</time_frame>
    <description>ESCULAP versus CEUS LI-RADS (diagnostic accuracy, interobserver agreement) Reference Standard: histology / MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inferiority of CEUS versus MRI for non-invasive diagnosis of HCC</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of CEUS and MRI for non-invasive diagnosis of HCC (diagnostic accuracy, interobserver agreement) Reference Standard: histology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of histological grading on contrast enhancement behaviour</measure>
    <time_frame>2 years</time_frame>
    <description>correlation of histological grading and contrast enhancement pattern</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Cholangiocarcinoma, Intrahepatic</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Liver Cancer</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>Patients at risk for HCC</arm_group_label>
    <description>Patients with any of the following conditions:
liver cirrhosis of any origin chronic hepatitis B infection chronic hepatitis C infection with advanced fibrosis non-alcoholic steatohepatitis (NASH) hemochromatosis
Interventions: B-mode ultrasound, contrast enhanced ultrasound (CEUS); MRI / histology</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>contrast enhanced ultrasound (CEUS)</intervention_name>
    <description>CEUS with SonoVue following standardized protocol</description>
    <arm_group_label>Patients at risk for HCC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>CE-MRI following standardized protocol</description>
    <arm_group_label>Patients at risk for HCC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Histology</intervention_name>
    <description>diagnostic liver biopsy</description>
    <arm_group_label>Patients at risk for HCC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        High-risk patients for HCC according to German national guidelines (AWMF / DGVS): 1-
        cirrhosis of any origin; 2- chronic hepatitis B infection; 3 - chronic hepatitis C
        infection; 4 - non-alcoholic steatohepatitis (NASH); 5 - hereditary hemochromatosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  high risk for HCC

          -  focal liver lesion on B-mode ultrasound

        Exclusion Criteria:

          -  pre-treated HCC lesion

          -  systemic therapy for HCC (sorafenib, regorafenib and others)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Schellhaas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen, Department of Medicine 1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deike Strobel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen, Department of Medicine 1</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Schellhaas, MD</last_name>
    <phone>0049(0)91318535000</phone>
    <email>barbara.schellhaas@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deike Strobel, MD</last_name>
    <phone>0049(0)91318535000</phone>
    <email>deike.strobel@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Erlangen, Department of Medicine 1</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Schellhaas, MD</last_name>
      <phone>0049(0)91318535000</phone>
      <email>barbara.schellhaas@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Deike Strobel, MD</last_name>
      <phone>0049(0)91318535000</phone>
      <email>deike.strobel@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Barbara Schellhaas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deike Strobel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Pfeifer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruediger S Goertz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maximilian J Waldner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.degum.de/aktivitaeten/wissenschaft/studien.html</url>
    <description>Homepage of the DEGUM (Funding Organization)</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Erlangen</investigator_affiliation>
    <investigator_full_name>Dr. med. Barbara Schellhaas and Prof. Dr. med. Deike Strobel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>contrast-enhanced ultrasound</keyword>
  <keyword>non-invasive diagnosis</keyword>
  <keyword>focal liver lesion</keyword>
  <keyword>liver cirrhosis</keyword>
  <keyword>standardised diagnostic algorithm</keyword>
  <keyword>intrahepatic cholangiocellular carcinoma</keyword>
  <keyword>ESCULAP</keyword>
  <keyword>CEUS LI-RADS</keyword>
  <keyword>imaging</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>MRI</keyword>
  <keyword>diagnostic accuracy</keyword>
  <keyword>interobserver agreement</keyword>
  <keyword>Erlanger Synopsis of CEUS for Liver lesion Assessment in Patients at risk</keyword>
  <keyword>CEUS Liver Imaging Reporting and Data System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

